The associations between synaptic density and "A/T/N" biomarkers in Alzheimer's disease: An 18 F-SynVesT-1 PET/MR study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: United States NLM ID: 8112566 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1559-7016 (Electronic) Linking ISSN: 0271678X NLM ISO Abbreviation: J Cereb Blood Flow Metab Subsets: MEDLINE
    • Publication Information:
      Publication: 2016- : Thousand Oaks, CA : SAGE Publications
      Original Publication: New York : Raven Press, c1981-
    • Subject Terms:
      Alzheimer Disease*/diagnostic imaging ; Alzheimer Disease*/metabolism ; Alzheimer Disease*/pathology ; Biomarkers* ; Synapses*/metabolism ; Synapses*/pathology ; Amyloid beta-Peptides*/metabolism; Humans ; Male ; Female ; Aged ; Middle Aged ; tau Proteins/metabolism ; Magnetic Resonance Imaging/methods ; Positron-Emission Tomography/methods ; Radiopharmaceuticals ; Positron Emission Tomography Computed Tomography/methods ; Cognitive Dysfunction/metabolism ; Cognitive Dysfunction/diagnostic imaging ; Membrane Glycoproteins/metabolism ; Fluorine Radioisotopes ; Nerve Tissue Proteins/metabolism ; Aged, 80 and over
    • Abstract:
      A newly developed SV2A radiotracer, 18 F-SynVesT-1, was used in this study to investigate synaptic density and its association with Alzheimer's disease (AD) "A/T/N" biomarkers. The study included a cohort of 97 subjects, consisting of 64 patients with cognitive impairment (CI) and 33 individuals with normal cognition (CU). All subjects underwent 18 F-SynVesT-1 PET/MR and 18 F-florbetapir PET/CT scans. Additionally, a subgroup of individuals also underwent 18 F-MK-6240, 18 F-FDG PET/CT, plasma Aβ42/Aβ40 and p-tau181 tests. The differences in synaptic density between the groups and the correlations between synaptic density and AD "A/T/N" biomarkers were analyzed. The results showed that compared to the CU group, the CI with Aβ+ (CI+) group exhibited the most pronounced synapse loss in the hippocampus, with some loss also observed in the neocortex. Furthermore, synaptic density in the hippocampus and parahippocampal gyrus showed associations with AD biomarkers detected by both imaging and plasma tests in the CI group. The associations between synaptic density and FDG uptake and hippocampal volume were also observed in the CI+ group. In conclusion, the study demonstrated significant synaptic density loss, as measured by the promising tracer 18 F-SynVesT-1, and its close correlation with "A/T/N" biomarkers in patients with both Alzheimer's clinical syndrome and pathological changes.
      Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
    • References:
      Neurology. 2019 Oct 22;93(17):e1647-e1659. (PMID: 31371569)
      Alzheimers Dement. 2018 Apr;14(4):535-562. (PMID: 29653606)
      Neurology. 2020 Aug 4;95(5):e545-e553. (PMID: 32493717)
      J Nucl Med. 2021 Apr;62(4):561-567. (PMID: 32859701)
      Ann Neurol. 1996 Jan;39(1):62-70. (PMID: 8572669)
      Neuroimage. 2017 Feb 15;147:669-677. (PMID: 28039094)
      Alzheimers Res Ther. 2021 Feb 5;13(1):35. (PMID: 33546722)
      Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):396-406. (PMID: 30121895)
      Neurobiol Aging. 2003 Dec;24(8):1023-7. (PMID: 14643374)
      Neuroimage. 2021 Sep;238:118248. (PMID: 34119639)
      Nat Med. 2020 Mar;26(3):379-386. (PMID: 32123385)
      J Cereb Blood Flow Metab. 2021 Sep;41(9):2395-2409. (PMID: 33757318)
      Lancet Neurol. 2010 Jan;9(1):119-28. (PMID: 20083042)
      J Nucl Med. 2019 Jan;60(1):93-99. (PMID: 29777006)
      JAMA Neurol. 2018 Oct 1;75(10):1215-1224. (PMID: 30014145)
      Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6820-5. (PMID: 19346482)
      J Alzheimers Dis. 2016 May 30;53(3):787-800. (PMID: 27258414)
      Mol Neurodegener. 2021 May 1;16(1):30. (PMID: 33933117)
      J Nucl Med. 2016 May;57(5):777-84. (PMID: 26848175)
      Nutrition. 2011 Jan;27(1):3-20. (PMID: 21035308)
      J Cereb Blood Flow Metab. 2021 Aug;41(8):1978-1987. (PMID: 33444094)
      Neuron. 2016 Mar 2;89(5):971-982. (PMID: 26938442)
      J Comput Assist Tomogr. 1995 Jul-Aug;19(4):541-7. (PMID: 7622680)
      Alzheimers Res Ther. 2016 Jan 15;8:2. (PMID: 26768154)
      Neuroimage. 2016 May 15;132:334-343. (PMID: 26915497)
      ACS Chem Neurosci. 2019 Mar 20;10(3):1544-1554. (PMID: 30396272)
      Alzheimers Res Ther. 2021 Jan 5;13(1):11. (PMID: 33402201)
      Front Aging Neurosci. 2022 Mar 23;14:832700. (PMID: 35401142)
      Neurology. 2013 Mar 5;80(10):890-6. (PMID: 23446680)
      J Cereb Blood Flow Metab. 2023 Jun;43(6):977-988. (PMID: 36718002)
      Nat Commun. 2021 Jul 14;12(1):4304. (PMID: 34262030)
      Mol Cell Neurosci. 2019 Jun;97:34-42. (PMID: 30796959)
      Brain. 2014 Sep;137(Pt 9):2578-87. (PMID: 25012223)
      Brain. 2021 Feb 12;144(1):310-324. (PMID: 33279949)
      J Neurosci. 2018 Dec 12;38(50):10595-10606. (PMID: 30355631)
      Lancet Neurol. 2020 May;19(5):422-433. (PMID: 32333900)
      Alzheimers Dement. 2020 Jul;16(7):974-982. (PMID: 32400950)
    • Contributed Indexing:
      Keywords: Synaptic vesicle glycoprotein 2A; amyloid-β deposition; cognitive performance; glucose metabolism; plasma biomarkers
    • Accession Number:
      0 (Biomarkers)
      0 (Amyloid beta-Peptides)
      0 (tau Proteins)
      0 (Radiopharmaceuticals)
      0 (Membrane Glycoproteins)
      0 (Fluorine Radioisotopes)
      0 (Nerve Tissue Proteins)
      148845-93-6 (SV2A protein, human)
    • Publication Date:
      Date Created: 20240131 Date Completed: 20240612 Latest Revision: 20240618
    • Publication Date:
      20240618
    • Accession Number:
      PMC11179616
    • Accession Number:
      10.1177/0271678X241230733
    • Accession Number:
      38295871